Culturelle vs Align: LGG or B. Infantis 35624 for Your Gut?

The one-line answer: Culturelle (Lactobacillus rhamnosus GG, "LGG") is the better-evidenced pick for preventing diarrhea — antibiotic-associated, pediatric, and traveler's — while Align (Bifidobacterium infantis 35624, now often reclassified as B. longum 35624) is the better-evidenced pick for IBS symptom relief specifically: bloating, abdominal pain and irregular bowel habits. They are single-strain products built for different jobs, and the more useful question isn't "which is the stronger probiotic" but "which problem are you actually trying to solve."

One Strain, One Job: Why These Two Don't Compete for the Same Symptom

Probiotic effects are strain-specific, not species-specific — a fact the supplement aisle's generic "probiotic blend" labeling routinely obscures. LGG and B. infantis 35624 are both well-characterized, individually patented strains with their own separate trial histories, and neither company markets its product as a general cure-all. That specificity is a strength here, not a limitation: it means the label's marketed use case is closely tied to the actual research, rather than a broad claim stretched across a strain never tested for it.

Head-to-Head Comparison

Shop Both on Amazon

Culturelle:

Affiliate disclosure: GutCode earns a commission on qualifying Amazon purchases at no additional cost to you.

Align:

Affiliate disclosure: GutCode earns a commission on qualifying Amazon purchases at no additional cost to you.

Culturelle: The Best-Studied Diarrhea-Prevention Strain

What it is and the evidence

LGG is one of the most-researched probiotic strains in existence, with decades of trial data concentrated on diarrhea outcomes. The Doron et al. 2011 meta-analysis, covering more than 4,700 participants, found LGG reduced the risk of antibiotic-associated diarrhea, and separate pediatric trials support its use for reducing the duration of infectious (often rotavirus) diarrhea in children. Evidence for LGG in IBS specifically is thinner and more mixed than its diarrhea data.

Pros

• Among the deepest trial histories of any single probiotic strain, spanning multiple independent research groups
• Higher CFU count gives more flexibility on dosing (once or twice daily) if a clinician recommends adjusting
• Inexpensive relative to most single-strain probiotics on the market

Cons

• Not the best-matched strain if your primary complaint is IBS-type bloating or pain rather than diarrhea risk
• Higher CFU count is not itself a reason to expect a stronger IBS effect — dose was optimized for diarrhea-prevention trials, not IBS trials

Align: The IBS-Focused, Low-Dose Specialist

What it is and the evidence

Align's single strain was originally classified as Bifidobacterium infantis 35624 and has since been reclassified under genomic analysis as Bifidobacterium longum 35624 (marketed outside the US under the name Alflorex). Its defining study, a randomized, double-blind trial by Whorwell and colleagues in 2006, found a meaningful reduction in composite IBS symptom scores — bloating, abdominal pain, and bowel-habit irregularity — in women with IBS, at a comparatively low dose of about 1 billion CFU.

Pros

• Purpose-built and trial-matched for IBS symptom relief specifically, not a generic "digestive health" claim
• Low CFU dose is intentional and matched to the studies that support it — not evidence of an under-dosed or weaker product
• Once-daily, simple routine

Cons

• Narrower evidence base outside IBS — not the strain to reach for if diarrhea prevention is the actual goal
• Slightly higher price band for a lower CFU count, which is easy to misread as a worse value if you don't know CFU isn't the deciding variable here

CFU Count Is a Red Herring Here

A 20-billion-CFU product sitting next to a 1-billion-CFU product on a shelf reads, to most shoppers, as "twenty times stronger." For strain-specific, dose-matched clinical research, that instinct is wrong. Align's 1 billion CFU dose is the dose used in the trials that support its IBS claim; taking more wouldn't be expected to produce a bigger effect, because that's not the variable the research tested. CFU count only matters as a comparison when you're comparing the same strain at different doses — comparing CFU across two entirely different strains, each dosed to match its own separate trial, tells you nothing about which will work better for you.

Can You Take Both, and Does Strain-Combining Even Help?

There's no known safety interaction between LGG and B. infantis 35624, and some people do take both if they have overlapping concerns (say, IBS plus a course of antibiotics coming up). But combining strains doesn't reliably produce an additive effect just because it sounds more thorough — each strain's trial evidence applies to that strain alone, taken alone, at its studied dose. If you have one clearly dominant symptom, matching the single most relevant strain to it is a more evidence-grounded approach than stacking both "just in case."

Verdict: Which One Matches Your Actual Problem

Choose Culturelle if your concern is diarrhea risk — starting antibiotics, traveling, or managing a child's GI symptoms — where LGG has the deepest and most consistent trial support of the two. Choose Align if you have diagnosed or clearly recurring IBS symptoms (bloating, cramping, irregular bowel habits), where its low, trial-matched dose of B. infantis 35624 has the more directly relevant evidence. If your situation doesn't clearly fit either — unexplained chronic GI symptoms, especially with red-flag signs like weight loss or blood in stool — that's a reason to see a clinician before choosing a probiotic at all, not a reason to pick the more expensive one.

For diarrhea prevention:

Affiliate disclosure: GutCode earns a commission on qualifying Amazon purchases at no additional cost to you.

For IBS symptom relief:

Affiliate disclosure: GutCode earns a commission on qualifying Amazon purchases at no additional cost to you.